The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

Dr. Celine Gounder joins CBS Mornings to break down the FDA-approved drug Lenacapavir, which is being called the closest step ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA).

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.